NCT03662074 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03662074
Title	Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Wake Forest University Health Sciences
Indications	lung small cell carcinoma
Therapies	Gemcitabine + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 1 of 1 entries

Facility	Status	City	State	Zip	Country	Details
Wake Forest University Health Sciences		Winston-Salem	North Carolina	27157	United States	Details

Showing 1 to 1 of 1 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03662074Clinical Trial Detail